carmot glp-1 Roche's $2.7B bet pays off with phase 1 weight loss success Carmot's CT-996 GLP-1 candidate supports
Description
The results of the PIONEER-3 trial have now been published in the renowned journal Journal of the American Medical Association (JAMA) and are said to be trend-setting for future therapy of type 2 diabetes.
Ryan OConnor, Professional Truck Driver (US)
For Research Use Only
Invitrogen Human GLP-1 (1-37a) ELISA Kit from Invitrogen&trade
